BLOCKTRANS GT
Interaction
May be prescribed with other antihypertensive drugs.
Losartan
There were no clinically significant pharmacokinetic interactions of the drug with drugs such as hydrochlorothiazide, digoxin, warfarin, cimetidine, phenobarbital, ketoconazole and erythromycin. Rifampicin reduces the concentration of the active metabolite. The clinical significance of this interaction has not been established. As with other agents that block the formation of angiotensin II and its effects, concomitant administration of potassium-sparing diuretics (spironolactone, triamterene, amiloride, eplerenone), potassium supplements and potassium-containing salts may lead to an increase in serum potassium. As with the use of other drugs that affect sodium excretion, treatment with losartan may be accompanied by a decrease in excretion and an increase in the serum concentration of lithium, therefore, during simultaneous treatment with lithium preparations, its serum concentration should be monitored.
Nonsteroidal anti-inflammatory drugs (NSAIDs), including selective COX-2 inhibitors, may reduce the effect of diuretics and other antihypertensive drugs. Therefore, the antihypertensive effect of angiotensin II receptor antagonists may be weakened by concomitant use of NSAIDs, including selective COX-2 inhibitors.
In some patients with impaired renal function who have been treated with NSAIDs, including selective COX-2 inhibitors, co-administration of angiotensin II receptor antagonists may cause a further deterioration of renal function, including acute renal failure. Usually this effect is reversible. Double blockade of the RAAS - the combined use of an angiotensin II receptor blocker with an ACE inhibitor - leads to a significant increase in the frequency of adverse events, such as arterial hypotension, fainting, hyperkalemia, renal dysfunction, acute renal failure. The highest risk is in patients with an established diagnosis of atherosclerosis, heart failure, diabetes mellitus (with any complication). The use of dual blockade of the RAAS (for example, by simultaneous administration of an ACE inhibitor and an angiotensin II receptor antagonist) should be decided on a case-by-case basis with careful monitoring of renal function.
Fluconazole, an inhibitor of the CYP2C9 isoenzyme, reduces plasma concentrations of the active metabolite and increases the concentrations of losartan, however, the pharmacodynamic significance of this phenomenon has not been established. It has been shown that individuals who do not metabolize losartan into the active metabolite have a very rare and specific defect in the CYP2C9 isoenzyme.
Hydrochlorothiazide
When used simultaneously with barbiturates, narcotic analgesics, and ethanol, orthostatic hypotension may develop. When used simultaneously with hypoglycemic drugs (for oral administration and insulin), dose adjustment of the hypoglycemic drugs may be required. Due to the risk of lactic acidosis due to possible renal impairment when using hydrochlorothiazide, metformin should be used with caution.
When used simultaneously with other antihypertensive drugs, an additive effect is observed.
Avoid simultaneous use with lithium salts (renal clearance of lithium decreases and its toxicity increases).
When used simultaneously with corticosteroids, adrenocorticotropic hormone, glycyrrhizic acid (found in licorice root), amphotericin B, a marked decrease in the content of electrolytes, especially potassium, occurs.
When used simultaneously with non-depolarizing muscle relaxants (tubocurarine), their effect may be enhanced.
NSAIDs, including selective COX-2 inhibitors, may reduce the diuretic, natriuretic and antihypertensive effects of hydrochlorothiazide. A single dose of cholestyramine or colestipol can reduce the absorption of hydrochlorothiazide in the gastrointestinal tract by 85 and 43%, respectively. With simultaneous use of the drug with pressor amines (norepinephrine, epinephrine), a slight decrease in the effect of pressor amines is possible. Medicines used to treat gout (probenecid, sulfinpyrazone and allopurinol) - dose adjustment may be required (increasing the dose of probenecid and sulfinpyrazone) as hydrochlorothiazide may increase serum uric acid concentrations. Concomitant use of thiazide diuretics may increase the incidence of hypersensitivity reactions to allopurinol. Anticholinergics (for example, atropine, biperiden) - increase the bioavailability of thiazide diuretics by reducing gastrointestinal motility and the rate of gastric emptying.
Thiazide diuretics may reduce the renal excretion of cytotoxic drugs (eg, cyclophosphamide, methotrexate) and enhance their myelosuppressive effect.
Thiazide diuretics may enhance the toxic effects of salicylates on the central nervous system when used in high doses.
Isolated cases of hemolytic anemia have been reported with the simultaneous use of hydrochlorothiazide and methyldopa.
Concomitant treatment with cyclosporine may increase the risk of hyperuricemia and gout.
Hypokalemia or hypomagnesemia caused by the use of thiazide diuretics can contribute to the development of arrhythmias when used simultaneously with cardiac glycosides.
Concomitant use of thiazide diuretics with antiarrhythmic drugs (quinidine, hydroquinidine, disopyramide, amiodarone, sotalol, dofetilide, ibutilide), some antipsychotic drugs (neuroleptics) (thioridazine, chlorpromazine, levomepromazine, trifluoperazine, cyamemazine, sulpiride, sultopride, amisulpride, tiapride, pi mosid, haloperidol, droperidol) and other drugs (bepridil, cisapride, difemanil, erythromycin, halofantrine, mizolastine, pentamidine, terfenadine, vincamine) may be accompanied by the development of hypokalemia, which, in turn, can cause the development of ar.
Thiazide diuretics can lead to hypercalcemia as a result of decreased excretion, so it is necessary to monitor serum calcium levels. Due to the effect of thiazide diuretics on calcium metabolism, their use may distort the results of studies of the function of the parathyroid glands.
When used simultaneously with carbamazepine, there is a risk of developing symptomatic hyponatremia.
With the development of dehydration during the use of diuretics, there is a possibility of developing acute renal failure, especially when used simultaneously with iodine preparations.
Brief information about the drug
The drug for high blood pressure Bloktran belongs to the pharmacological group of angiotensin 2 receptor antagonist drugs. It is produced in Russia.
Release form
The blood pressure medicine Blocktran is presented on the pharmaceutical market in a convenient tablet form. The manufacturer produces tablets packaged in blisters of 10 pieces. You can purchase either 1 blister or a box containing 2, 3, 5 or 6 blisters.
Packaging of Blocktran tablets
Composition of tablets
The main active component of the drug is potassium losartan, presented in a dose of 12.5 mg or 50 mg.
The composition of the tablets also includes additional ingredients: starch, sodium carboxymethyl starch, magnesium stearate, lactose monohydrate, povidone, silicon dioxide, microcrystalline cellulose.
Terms and conditions of storage
The tablets should be stored in a place inaccessible to children and pets, protected from moisture and direct sunlight. The recommended storage temperature should not exceed +30°C.
The maximum shelf life of the drug is 2 years.
Terms of sale
It is possible to purchase medication in pharmacy chains only after presenting an appropriate medical prescription.
Price
The cost of the drug is influenced by factors such as the dosage of the main active ingredient and the number of tablets in the package. The approximate price for Blocktran varies from 150 rubles to 400 rubles.
Pharmacological characteristics
The drug Bloktran has a pronounced antihypertensive pharmacological effect.
Manifestations of side effects
Treatment with Blocktran tablets can cause the following adverse reactions:
- Arterial hypotension (excessive decrease in blood pressure);
- Pulse abnormalities (tachycardia or bradycardia);
- Decreased sexual desire;
- Erectile dysfunction in male patients;
- Rhinitis;
- Convulsive syndrome;
- Increased urge to empty the bladder;
- Cough syndrome;
- Conjunctivitis;
- Noise and ringing in the ears;
- Deterioration of visual function;
- Diarrhea or constipation;
- Dyspeptic disorders;
- Bronchitis;
- Dizziness;
- Migraine attacks;
- Depressive states;
- Nausea and vomiting;
- Toothache;
- Permanent lack of appetite, up to anorexia;
- Painful sensations localized in the sternum, lower extremities, back, knee joint, shoulder region;
- Skin itching;
- Rash on the skin like urticaria;
- Anemia;
- Tremor;
- Problems with sleep (insomnia or increased sleepiness);
- Chronic fatigue syndrome, weakness, asthenia, decreased performance;
- Hair loss;
- Increased sweating;
- Excessive dryness of the skin;
- Memory impairment;
- Psycho-emotional instability, causeless nervousness, anxiety, restlessness.
In most cases, the drug is well tolerated, and possible side effects disappear on their own after a few days of treatment. If the condition worsens, you should definitely inform your doctor about it!
Lack of appetite may be a side effect of taking the pills
Important Notes
During the therapeutic course, it is necessary to regularly monitor potassium levels in the blood, especially if we are talking about elderly people or patients with diagnosed renal dysfunction.
Before starting treatment, it is recommended to correct dehydration. If this cannot be done for certain reasons, then therapy begins with minimal dosages of the drug.
In patients suffering from dehydration, tablets can provoke the development of a hypotensive crisis.
Is it possible to drive a car?
Possible side effects of Bloktran include dizziness, increased drowsiness, and asthenia. For this reason, in the first days of the therapeutic course you should refrain from driving. In the future (if the condition is normal and there are no undesirable reactions from the central nervous system), the patient can get behind the wheel, using extreme caution.
Driving a car while taking Blocktran is possible in the absence of adverse reactions to the drug
When use is contraindicated
Medical specialists categorically prohibit drinking Blocktran for high blood pressure in patients who have the following clinical contraindications:
- Dehydration;
- Hypotonic disease (stably reduced blood pressure);
- Hyperkalemia;
- Individual intolerance and hypersensitivity to substances included in the tablets.
With particular caution, the drug is prescribed to persons with diagnosed liver failure or renal dysfunction. Treatment of this category of patients requires strict medical supervision, individual dosing and constant monitoring of health status.
Pharmacodynamics - increases or decreases blood pressure
Blood pressure tablets Blocktran suppress specific angiotensin receptors localized in the area of blood vessels, adrenal glands, heart and kidney apparatus.
Blocktran lowers blood pressure. Since the drug has a cumulative effect, the hypotensive effect becomes most noticeable after a month of the therapeutic course.
Bloktran is effective when used as a course
Increases renin levels in the blood without negatively affecting the production and functioning of other hormones responsible for the normal functioning of the cardiovascular system, which avoids a number of side effects characteristic of most antihypertensive drugs.
Helps increase life expectancy in patients suffering from cardiac ventricular hypertrophy and hypertension.
Drug interactions
Combination with potassium-containing drugs and diuretics increases the likelihood of developing hyperkalemia.
Tablets can be combined with other antihypertensive medications, diuretics, beta-blockers, but in smaller doses, due to an increased hypotensive effect.
You should ask your doctor about compatibility with other drugs.
